vertigo from semaglutide GLP-1 Injections Electrolytes for GLP-1 Dizziness: Why
Description
We report the use of GLP-1RA therapy with liraglutide and subsequent transition to subcutaneoussemaglutide weekly in a 37-year-old female with severe obesity, weighing 694 lbs (314 kg) with a body mass index (BMI) of 108 kg/m2
Here's what to know and what to do about it.
And it's clear that these medications have significant potential to not only meaningfully improve patient outcomes, but also to reshape the business models underlying chronic care today
Explore semaglutide treatment in Phoenix, AZ
